Showing results (601-610 of 995) with videos related to
Sort By:
Pageof 100
The FEBS Journal|November 10, 2009
Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathwaysDaniela Berg, Thorsten Stühmer, Daniela Siegmund, et al.Neurobiology of Disease|December 26, 2006
Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP modelWalter Maetzler, Daniela Berg, Natalie Schalamberidze, et al.Cells|July 11, 2025
Neurofilament Light Chain in Serum and CSF as a Potential Biomarker for Primary Angiitis of the Central Nervous SystemChristina Krüger, Hans Pinnschmidt, Maximilian Wilmes, et al.Brain Stimulation|September 26, 2018
Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trialDoreen Gruber, Martin Südmeyer, Günther Deuschl, et al.The Lancet. Neurology|September 18, 2010
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]Alex Iranzo, Francisco Lomeña, Heike Stockner, et al.Movement Disorders : Official Journal of the Movement Disorder Society|July 18, 2013
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's diseaseRichard Dodel, Bengt Jönsson, Jens Peter Reese, et al.Clinical Neuropharmacology|January 18, 2014
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized studyMurat Emre, Werner Poewe, Peter Paul De Deyn, et al.Neurology|March 13, 2020
Seeing ophthalmologic problems in Parkinson disease: Results of a visual impairment questionnaireCarlijn D J M Borm, Femke Visser, Mario Werkmann, et al.Neurology|March 13, 2020
Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorderAlex Iranzo, Ambra Stefani, Aida Niñerola-Baizan, et al.Journal of Neurology|August 20, 2024
Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studiesJoaquim J Ferreira, Jee-Young Lee, Hyeo-Il Ma, et al.Pageof 100